2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Michael Roth: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF) - Scleroderma, Systemic, Interstitial Lung Disease | Phase 2 | Completed | Michael Roth | 51 | 2017-11-28 | 2023-12-15 |
| Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Mycophenolate mofetil, Cyclophosphamide, Placebo - Scleroderma, Interstitial Lung Disease | Phase 2 | Completed | Michael Roth | 142 | 2009-09-01 | 2017-02-10 |
Lung Diseases, Interstitial (2) · Scleroderma, Systemic (2) · Dyspnea (1) · Scleroderma, Diffuse (1)
Mycophenolic Acid (2) · 5'-palmitoyl cytarabine (1) · Cyclophosphamide (1) · Drugs, Generic (1) · Sugars (1) · pirfenidone (1)
United States (2)
Donald P. Tashkin, MD (1) · Michael D Roth, MD (1) · Michael D. Roth, MD (1) · Robert M. Elashoff, PhD (1)
PMID 15692967, PMID 16790698, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 18641099, PMID 19776222, PMID 19892673, PMID 20740615, PMID 25452309, PMID 27469583, PMID 28012804, PMID 28038680, PMID 28544580, PMID 29099620, PMID 30651141, PMID 31430058, PMID 33287583, PMID 33350170, PMID 41316297
R01HL089758 (1), R01HL089901 (1)